SAPA-NE 24th Annual Conference
Sat, Sep 24
|Zoom Webinar
New Era and Unprecedented Opportunities for Developing Novel Therapies


Event Time
Sep 24, 2022, 9:00 AM – 4:00 PM
Zoom Webinar
About the Event
SAPA-NE 24th Annual Conference: New Era and Unprecedented Opportunities for Developing Novel Therapies
Saturday, Sep 24, 2022, 9 AM – 4 PM EDT (美东时间)
Free Zoom Webinar [Agenda] [Brochure]
The event features presentations and panel discussions presented by distinguished speakers/panelists in academic or industry.
Topics include:
Future of Drug Discovery and Development
New Modality Platforms and Frontiers
Enabling Technology Advancement and Applications
Targeted Drug Delivery
Future of Drug Discovery and Development
Dr. Hong Shen, SVP, Roche China, The journey of the China Innovation Center of Roche (CICoR)
Dr. Tommy Vaughan, Professor, Columbia University, MRI for the World
New Modality Platforms and Frontiers
Dr. Leo Qian, Co-Founder and VP, Entrada Therapeutics, Endosomal Escape Vehicle (EEV) Platform to Enhance the Functional Delivery of Oligonucleotides
Mr. Saket Agarwal, Scientist, Alnylam Pharmaceuticals, Recent Advances in Delivery of RNAi Therapeutics to the CNS
Dr. Guoqiang Wang, VP, Chemistry at Ranok Therapeutic, Chaperone-mediated Protein Degradation (CHAMP™): A Tumor-targeted Protein Degrader Technology
Dr. Shuling Guo, VP, Ionis Pharmaceuticals, RNA Therapeutics--A Versatile Drug Discovery Platform
Enabling Technology Advancement and Applications
Dr. James Jin, VP, Biocytogen Boston Corp, Gene engineered mouse models (GEMMs) in drug discovery
Chris Moore and Zach Houston, Perkin Elmer, Visualizing the effects of therapy with Vega and IVIS preclinical imaging platforms
Dr. Santi Chen, Associate Director, GemPharmatech, Supporting Preclinical Research and Drug Development with Cutting-Edge GEMMs and Services
Targeted Drug Delivery
Dr. Qiaobing Xu, CEO, Hopewell Therapeutics/Professor, Tufts University, Synthetic Biodegradable Lipid Nanoparticles for Gene Therapy and Gene Editing
Dr. Steve Kates, VP, Regulatory Affairs, Dicerna, GalXC™ and GalXC-Plus™ RNAi Technologies: From Bench to Clinic
Career Development Panel Discussion
Dr. Huijuan Li, VP, Moderna & Panelists from Moderna, BMS and Beam Therapeutics, Successful Career in Bio-Pharmaceutical Industry
(Note: All sales are final and NO refund shall be issued.)
Register Now
Regular Ticket
$0.00
Sale ended